ELSEVIER

Toxicology 143 (2000) 293

TOXICOLOGY

www.elsevier.com/locate/toxicol

Author index of volume 143

Abdel-Naim, A.B. **143**, 217
Abdel-Wahab, M.H. **143**, 217

Badary, O.A. **143**, 217
Barker, E. **143**, 123
Barton, C.C. **143**, 165
Bellocchio, A. **143**, 281
Bhandari, N. **143**, 181
Bucci, T.J. **143**, 165

Campbell, P.A. **143**, 233
Colosio, C. **143**, 5
Cottalasso, D. **143**, 281

Del Razo, L.M. **143**, 153
Domenicotti, C. **143**, 281

Fait, A. **143**, 5
Farris, G.M. **143**, 123
Ferioli, A. **143**, 5
Fontana, L. **143**, 281
Frome, E.L. **143**, 123

Gardner, R. **143**, 207
Gavett, S.H. **143**, 139

Habbersett, R.C. **143**, 123
Hamada, F.M.A. **143**, 217
Hamada, H. **143**, 233, 247
Hughes, M.F. **143**, 153

Jin, T. **143**, 225

Kaneko, T. **143**, 201
Kenyon, E.M. **143**, 153
Kittle, L.A. **143**, 233, 247
Klaassen, C.D. **143**, 193
Kolaja, K.L. **143**, 193

Leffler, P.E. **143**, 225
Lomax, L.G. **143**, 165

Madison, S.L. **143**, 139
Maier, L. **143**, 123
Maroni, M. **143**, 1
Marrone, B.L. **143**, 123
Mehendale, H.M. **143**, 165
Meredith, F.I. **143**, 181
Moreno, J.J. **143**, 273

Nanni, G. **143**, 281
Newman, L.S. **143**, 123, 233, 247
Nordberg, G.F. **143**, 225
Norese, R. **143**, 281

O'Brien, P.J. **143**, 261

Petrick, J.S. **143**, 193
Pourahmad, J. **143**, 261
Pronzato, M.A. **143**, 281

Riley, R.T. **143**, 181

Sailstad, D.M. **143**, 139
Sato, A. **143**, 201
Sawyer, R.T. **143**, 233, 247
Selgrade, M.J.K. **143**, 139
Sharma, R.P. **143**, 181
Shou, Y. **143**, 123
Smith, H.N. **143**, 123
Spangler, F. **143**, 207

Voss, K.A. **143**, 181

Wang, P.-Y. **143**, 201
Warbritton, A.G. **143**, 165
Ward, M.D.W. **143**, 139

PII: S0300-483X(00)00151-7

ELSEVIER

Toxicology 143 (2000) 295–298

TOXICOLOGY

www.elsevier.com/locate/toxicol

Subject index of volume 143

Antigen; Fugus; Mouse **143**, 139

Antioxidant; Thymoquinone; Doxorubicin; Nephropathy; Hyperlipidemia **143**, 217

ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

AP-1; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Apoptosis; Thyroid; Gap-junctional-intercellular communication **143**, 193

ARDS; ANTU; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Arsenic; Dimethylarsinic acid; Pharmacokinetics **143**, 153

Autologous plasma; Beryllium; Lymphocyte proliferation test; Flow cytometry; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Beryllium; Chronic beryllium disease; Tumor necrosis factor-α; Interferon-γ; Hybrid macrophages; Lipopolysaccharide **143**, 233

Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

BrdU; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Bzip proteins; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Cadmium; Hepatocyte; Copper; Oxidative stress; Mitochondria **143**, 261

Cadmium-metallothionein; Nephrotoxicity; Renal membrane vesicles; Calcium transport; Rat **143**, 225

Calcium transport; Nephrotoxicity; Renal membrane vesicles; Cadmium-metallothionein; Rat **143**, 225

CD8; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

CD4; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Chronic beryllium disease; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus **143**, 123

Chronic beryllium disease; Beryllium; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Chronic beryllium disease; Beryllium; Tumor necrosis factor-α; Interferon-γ; Hybrid macrophages; Lipopolysaccharide **143**, 233

PII: S0300-483X(00)00149-9

Colchicine; ANTU; ARDS; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Copper; Hepatocyte; Cadmium; Oxidative stress; Mitochondria **143**, 261

CREB; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Cyclooxygenase; Skin irritancy; Eicosanoids; Phospholipase A_2; Toxicology in vitro **143**, 273

DAPI; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; PI; Tetanus; Chronic beryllium disease **143**, 123

1,2-Dichloroethane; Vitamin E; Dolichol; Liver; Golgi apparatus **143**, 281

Dimethylarsinic acid; Pharmacokinetics; Arsenic **143**, 153

Dolichol; Vitamin E; 1,2-Dichloroethane; Liver; Golgi apparatus **143**, 281

Doxorubicin; Thymoquinone; Antioxidant; Nephropathy; Hyperlipidemia **143**, 217

Eicosanoids; Skin irritancy; Phospholipase A_2; Cyclooxygenase; Toxicology in vitro **143**, 273

Epidermal growth factor receptor; ANTU; ARDS; Colchicine; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Flow cytometry; Beryllium; Lymphocyte proliferation test; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Fugus; Mouse; Antigen **143**, 139

Fumonisin; Tumor necrosis factor; Tumor necrosis factor receptor; Hepatotoxicity; Mice; TNF receptor knockout mice; NFκB **143**, 181

Gap-junctional-intercellular communication; Apoptosis; Thyroid **143**, 193

Golgi apparatus; Vitamin E; 1,2-Dichloroethane; Dolichol; Liver **143**, 281

Hepatocyte; Cadmium; Copper; Oxidative stress; Mitochondria **143**, 261

Hepatotoxicity; Fumonisin; Tumor necrosis factor; Tumor necrosis factor receptor; Mice; TNF receptor knockout mice; NFκB **143**, 181

Hybrid macrophages; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Hybrid macrophages; Beryllium; Chronic beryllium disease; Tumor necrosis factor-α; Interferon-γ; Lipopolysaccharide **143**, 233

Hyperlipidemia; Thymoquinone; Antioxidant; Doxorubicin; Nephropathy **143**, 217

Hyperplasia; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Hypersensitivity; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Immunophenotyping; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Interferon-γ; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Interferon-γ; Beryllium; Chronic beryllium disease; Tumor necrosis factor-α; Hybrid macrophages; Lipopolysaccharide **143**, 233

Keratinocyte growth factor; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Lipopolysaccharide; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Lipopolysaccharide; Beryllium; Chronic beryllium disease; Tumor necrosis factor-α; Interferon-γ; Hybrid macrophages **143**, 233

Liver; Vitamin E; 1,2-Dichloroethane; Dolichol; Golgi apparatus **143**, 281

Lung; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Paraquat; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Lymphocyte proliferation test; Beryllium; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Tetanus; Chronic beryllium disease **143**, 123

Macrophages; Beryllium; Chronic beryllium disease; Transcription factors; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Mice; Fumonisin; Tumor necrosis factor; Tumor necrosis factor receptor; Hepatotoxicity; TNF receptor knockout mice; NFκB **143**, 181

Mitochondria; Hepatocyte; Cadmium; Copper; Oxidative stress **143**, 261

Mouse; Fugus; Antigen **143**, 139

Nephropathy; Thymoquinone; Antioxidant; Doxorubicin; Hyperlipidemia **143**, 217

Nephrotoxicity; Renal membrane vesicles; Cadmium-metallothionein; Calcium transport; Rat **143**, 225

NFκB; Fumonisin; Tumor necrosis factor; Tumor necrosis factor receptor; Hepatotoxicity; Mice; TNF receptor knockout mice **143**, 181

NF-κB/IκBα; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Organic solvent; Partition coefficient; Plasma triglyceride level; Physiologically based pharmacokinetic model **143**, 201

Oxidative stress; Hepatocyte; Cadmium; Copper; Mitochondria **143**, 261

Paraquat; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Permeability; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Partition coefficient; Organic solvent; Plasma triglyceride level; Physiologically based pharmacokinetic model **143**, 201

Permeability; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Resistance; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Pharmacokinetics; Dimethylarsinic acid; Arsenic **143**, 153

Phospholipase A_2; Skin irritancy; Eicosanoids; Cyclooxygenase; Toxicology in vitro **143**, 273

Physiologically based pharmacokinetic model; Partition coefficient; Organic solvent; Plasma triglyceride level **143**, 201

PI; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; Tetanus; Chronic beryllium disease **143**, 123

Plasma triglyceride level; Partition coefficient; Organic solvent; Physiologically based pharmacokinetic model **143**, 201

Rat; Nephrotoxicity; Renal membrane vesicles; Cadmium-metallothionein; Calcium transport **143**, 225

Renal membrane vesicles; Nephrotoxicity; Cadmium-metallothionein; Calcium transport; Rat **143**, 225

Resistance; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Transforming growth factor-alpha; Transforming growth factor-beta **143**, 165

Skin irritancy; Eicosanoids; Phospholipase A_2; Cyclooxygenase; Toxicology in vitro **143**, 273

Tetanus; Beryllium; Lymphocyte proliferation test; Flow cytometry; Autologous plasma; CD4; CD8; Immunophenotyping; Hypersensitivity; BrdU; DAPI; PI; Chronic beryllium disease **143**, 123

Thymoquinone; Antioxidant; Doxorubicin; Nephropathy; Hyperlipidemia **143**, 217

Thyroid; Apoptosis; Gap-junctional-intercellular communication **143**, 193

TNF-α promoter; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α **143**, 247

TNF receptor knockout mice; Fumonisin; Tumor necrosis factor; Tumor necrosis factor receptor; Hepatotoxicity; Mice; NFκB **143**, 181

Toxicology in vitro; Skin irritancy; Eicosanoids; Phospholipase A_2; Cyclooxygenase **143**, 273

Transcription factors; Beryllium; Chronic beryllium disease; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopolysaccharide; Interferon-γ; Tumor necrosis factor-α; TNF-α promoter **143**, 247

Transforming growth factor-alpha; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-beta **143**, 165

Transforming growth factor-beta; ANTU; ARDS; Colchicine; Epidermal growth factor receptor; Hyperplasia; Keratinocyte growth factor; Lung; Paraquat; Permeability; Resistance; Transforming growth factor-alpha **143**, 165

Tumor necrosis factor-α; Beryllium; Chronic beryllium disease; Interferon-γ; Hybrid macrophages; Lipopolysaccharide **143**, 233

Tumor necrosis factor-α; Beryllium; Chronic beryllium disease; Transcription factors; Macrophages; Hybrid macrophages; NF-κB/IκBα; AP-1; CREB; Bzip proteins; Lipopol-ysaccharide; Interferon-γ; TNF-α promoter **143**, 247

Tumor necrosis factor; Fumonisin; Tumor necrosis factor receptor; Hepatotoxicity; Mice; TNF receptor knockout mice; NFκB **143**, 181

Tumor necrosis factor receptor; Fumonisin; Tumor necrosis factor; Hepatotoxicity; Mice; TNF receptor knockout mice; NFκB **143**, 181

Vitamin E; 1,2-Dichloroethane; Dolichol; Liver; Golgi apparatus **143**, 281